Royalty Report: Drugs, Cancer, Therapeutic – Collection: 2512


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 8


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8

Primary Industries

  • Drugs
  • Cancer
  • Therapeutic
  • Pharmaceuticals
  • Disease
  • Acne
  • Skin care

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 2512

License Grant
This agreement grants the Company an exclusive world-wide license to patents, patent applications, and other intellectual property related to GCS-100 Material.
License Property
The Company's lead drug candidate GCS-100 (formerly known as GBC-590), a potential treatment for multiple forms of cancer, recently completed Phase II(a) clinical trials for pancreatic cancer and completed Phase II(a) clinical trials for colorectal cancer in 2001.
Field of Use
The rights granted apply to the medical industry.

IPSCIO Record ID: 2369

License Grant
A former Chairman, CEO and Director, has granted the Company, subsidiary an exclusive, world-wide license, including the right to sublicense, for all products covered by certain patents, (if and when granted) or patent applications that he has developed (including GCS-100).
License Property
GCS-100–formerly known as GBC-590, a potential treatment for multiple forms of cancer.
Field of Use
The rights granted apply to the medical industry relating to oncology.

IPSCIO Record ID: 393

License Grant
Licensors hereby grant to Licensee, and Licensee hereby accepts, an exclusive, worldwide, royalty-bearing license under the Licensed Patents and Licensed Technology, including the right to grant sublicenses and the right to make, have made, use, lease and sell Licensed Products.
License Property
GBC-590 Material means products which utilize modified citrus pectin in connection with the Galectin 3 receptor, including, without limitation, those described in the Licensed Patents.

Licensed Patents means (i) U.S. Patent No. 5,895,784, entitled Method for Treatment of Cancer by Oral Administration of Modified Pectin; (ii) U. S. Patent No. 5,834,442, entitled Method for Inhibiting Cancer Metastasis by Oral Administration of Soluble Modified Citrus Pectin; (iii) any U.S. patent application filed as a continuation, continuation-in-part or division of the patents or patent applications, (iv) any foreign applications or patents which are counterparts to the U.S. patents; (v) any foreign applications or patents which are counterparts to the U.S. patents and (vi) any patents which issue from applications.  The Company and University agreed to a license and patents for cancer drug.  Now in phase 2 clinical trials for pancreatic and colorectal cancers, the drug, called GBC-590.

Field of Use
The rights granted apply to the medical industry.

IPSCIO Record ID: 26125

License Grant
A  portion of this intellectual property is owned by the Licensor and granted to the Company through an exclusive licensing agreement with Licensor, non-profit academic medical center.
License Property
One of the curaxins from the 9-aminoacridine group is a long-known anti-infective compound known as quinacrine, which we refer to as Curaxin CBLC102. It has  been  used for over 40 years to treat malaria, osteoarthritis and autoimmune disorders. However, we have discovered new mechanisms of action for quinacrine in the area of apoptosis. Through assay testing performed at Dr. Andrei Gudkov's laboratories beginning in 2002, which included testing  in a variety of human tumor-derived cell lines representing cancers of different  tissue origin (including RCC sarcomas, prostate, breast and colon carcinomas),  we have observed that Curaxin CBLC102 behaves as a potent NF-kB suppressor and  activator of p53 in these types of cancer cells. It has favorable  pharmacological and toxicological profiles and demonstrates the anticancer  effect in transplants of human cancer cells into primates. These features make  Curaxin CBLC102 our prime IND drug candidate among other curaxins. The drug  candidate is currently in Phase II clinical trials for treatment of hormone  refractory prostate cancer.  We also intend to conduct additional Phase II  clinical trials with Curaxin CBLC102 for RCC and multiple myeloma.
Field of Use
The rights granted apply to the healthcare industry.  Licensee is engaged in the discovery, development and commercialization of products for cancer treatment and protection of normal tissues from radiation and toxins.

IPSCIO Record ID: 25940

License Grant
An Australian Company signed a License for the clinical development, marketing and distribution of BrachySil in China. Under the terms of the License, we will manufacture BrachySil and Licensee will be responsible for clinical development, securing regulatory approval, marketing and distribution in China and Hong Kong. We will retain manufacturing rights for BrachySil under the License.
License Property
BrachySil, the company's lead BioSilicon application, is a targeted oncology product, which is presently in Phase II clinical trials for the treatment of both primary liver cancer and pancreatic cancer.

The technology company is about half way through U.S. regulatory testing of its modified silicon product BioSilicon that allows tiny pieces of radioactive material to be directly injected into primary liver tumours, as opposed to traditional radiotherapy that involves hitting a broader area with radiation.

Field of Use
“Licensed Field” 32P BioSilicon microparticles for use as a radiotherapy agent for the treatment or monitoring of solid cancerous tumours, including the primary tumour and metastases, which can be applied

i) interstitially within a cancerous tumour;

ii) into a resection cavity after surgical removal of a cancerous tumour;

iii) into the peritoneal cavity; or

iv) via the vasculature ( to the extent it becomes technically feasible).

IPSCIO Record ID: 1977

License Grant
The Company entered into an exclusive sublicense agreement to manufacture and market DENSPM for all cancer indications; thermogenhylnorspermine (DENSPM), is in a Phase II clinical trial for the treatment of various solid tumor cancers – clinical trial.

IPSCIO Record ID: 359135

License Grant
Licensor entered into a license agreement with Chinese Licensee, thereby granting to Licensee exclusive rights to commercialize Licensor's monoclonal antibody, Pritumumab, in international markets, excluding North America and Central America.
License Property
Pritumumab, a drug candidate using monoclonal antibodies for the treatment of various cancer types. Pritumumab may offer an advantage over existing treatments. Pritumumab works by binding to a target on the surface of cancer cells called ectodomain vimentin (also referred to as cell-surface vimentin). The target, generally referred to as an antigen, is prevalent in many different tumor types and is not being targeted by any other biopharmaceutical companies. By binding to this target, Pritumumab is able to make the tumor cells “known” to the body’s immune system, resulting in potentially several types of immune responses, including anti-idiotype, apoptosis, antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity, leading to death of the cancer cells and overall depletion of the tumor.
Field of Use
Field of use is for the treatment of brain cancer and pancreatic cancer and exploring in its use against viruses.

IPSCIO Record ID: 221650

License Grant
The Company assumed, following the transfer of an in-process research and development product candidate (hereafter — the product), an agreement for the development, manufacturing and commercialization of this product. According to this agreement, the Licensor will conduct all regulatory, scientific, clinical and technical activities necessary to develop the product.
License Property
The lead product candidate, TWIN, is a novel, once-daily, non-antibiotic topical cream that we are developing for the treatment of acne vulgaris, or acne. The company recently completed a 726 subject, double-blind, placebo-controlled, six-arm, multi-center Phase II clinical trial designed to assess the safety and efficacy of TWIN in subjects with facial acne. In this trial, TWIN demonstrated statistically significant improvements in all pre-defined co-primary and secondary efficacy endpoints, as compared to vehicle.  Subject to an End of Phase II meeting to be scheduled with the FDA, we plan to initiate two pivotal Phase III trials for TWIN in the United States in the second half of 2018 and expect to report top-line data from these trials in 2019. The other branded product candidates are SIRS-T, a topical cream containing encapsulated tretinoin for the potential treatment of acne; and VERED, a potential treatment for subtype II rosacea.

The product candidate pipeline consists of late-stage branded product candidates that leverage the proprietary, silica-based microencapsulation technology platform, and several generic product candidates across multiple indication.

Licensor is a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases.

Field of Use
This agreement pertains to the drug industry relating to the treatment of skin diseases.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.